Rosen Law Firm is encouraging investors who bought Corcept Therapeutics common stock between Oct. 31, 2024 and Dec. 30, 2025 to seek legal counsel ahead of an April 21, 2026 deadline to move for lead plaintiff status in a securities class action. The lawsuit alleges the company misled investors about the strength of clinical trial evidence and FDA communications supporting its relacorilant new drug application for hypercortisolism, and that undisclosed FDA concerns created a material risk the application would not be approved, causing investor losses when the information emerged.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Corcept Therapeutics Incorporated published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603021542PRIMZONEFULLFEED9664277) on March 02, 2026, and is solely responsible for the information contained therein.